4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Dogwood Therapeutics, Inc. (DWTX) operates in the Biotechnology industry and is headquartered in Alpharetta, United States with about 8 employees. Its market capitalization is roughly $48 million. In the fiscal year ended 2025-12-31, DWTX reported $0M in revenue and ($34M) in net income.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($28M) | ($12M) | ($5M) | ($12M) | — |
| Net Income | ($34M) | ($12M) | ($5M) | ($12M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($5M) | ($4M) | ($16M) | ($4M) | ($4M) |
| Net Income | ($5M) | ($4M) | ($16M) | ($4M) | ($11M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | — | — | — | — | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $90M | $94M | $4M | $8M |
| Total Liabilities | $15M | $30M | $0M | $1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DWTX viewer.
About TickerBase · Data methodology & sources